Kuruvilla: Philip Morris rates higher in ESG databases than lung cancer drugmakers
Finny Kuruvilla · Finny Kuruvilla – The Fourth Source of Alpha at Eventide (EP.343) · Oct 12, 2023 · at 22:03
Finny Kuruvilla, Co-CIO of Eventide Asset Management, critiques conventional ESG rating methodologies for relying on superficial disclosure checklists rather than core product impact.
0:00 / 0:15exact quote · 15.9s
720p mp4 · rendered on demand · StarZero watermark
“So we have often marveled that Philip Morris, which is a widely known provisioner of cigarettes and tobacco, rates more highly on many of these databases than on companies that are actually trying to treat lung cancer.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Finny Kuruvilla
Kuruvilla: Multi-stakeholder value-creating businesses outperform purely financial-focused companies long-term
“The thesis is that those types of businesses that are creating value for its stakeholders will outperform over the long haul in general, those businesses that are focusing only on one form of capital, i.e. Financial capital.”
Kuruvilla: Studies suggest values-driven investing yields 3% annualized alpha
“I think the best studies out there would suggest that there's somewhere in the neighborhood of three percent annualized alpha that the market hasn't captured while controlling for size and market cap and all the standard factors there that is to be harvested.”
Kuruvilla: Deep domain expertise provides the real edge against Wall Street
“The basic line that Peter Lynch hammers home is that there's a few disciplines you need to learn in terms of accounting and some basic knowledge about investing, but the real edge that you can have to beat Wall Street is if you have deep domain expertise in a …”
Kuruvilla: Much of biotech makes minor drug tweaks to charge $300k
“Okay, so a lot of biotech, unfortunately, is based on taking something that's already out there and tweaking it very, very slightly, changing a few atoms here and there in order to get a patent worth 20 years of life, and then going to market there with an inc…”
Kuruvilla: A 10% edge in biotech trial forecasting creates outsized alpha
“It's the same thing in our field here, where if you can be even 10% better than the average, then you're going to be an all star because these events tend to be so Dramatic. So companies can go up two or three fold, a hundred percent, 200% moves overnight, or …”